HOME >> BIOLOGY >> NEWS
Keeping autoimmunity in check may depend on balance in the immune system

(PHILADELPHIA - April 16, 2002) - Scientists know that the potential to generate dangerous antibodies that attack our own cells and tissues - one of the defining characteristics of autoimmune disorders like lupus - exists in everyone. That potential is unrealized in healthy individuals, but spins out of control in those who develop disease. So, what are the factors that push the potential for producing these antibodies into action and cause autoimmunity in some individuals? A new study from researchers at The Wistar Institute suggests that health depends on maintaining a balance of normal, but countervailing processes in the immune system. New approaches to developing treatments for autoimmunity might focus on influencing this balance.

In lupus and other autoimmune diseases, antibodies against our own cells and tissues are produced by B cells. The body contains billions of B cells that can make antibodies that target infecting viruses and bacteria, but these antibodies can also include ones that can react with "self" - an immunologist's term for our own bodies. One process that normally prevents these B cells from causing harm is that their activity depends on receiving "help" from T helper cells that also become stimulated when an infection occurs. However, another kind of T cell, called a regulatory T cell, may be important in preventing T helper cells from activating B cells with the potential to generate self-reactive antibodies.

Under normal circumstances, according to the Wistar study, a critical balance may exist between T helper cells and regulatory T cells. The researchers saw that providing T helper cells to healthy mice could cause autoreactive B cells to become active, and that removing T helper cells could alleviate disease in lupus-prone mice. They also found that regulatory T cells could stop T helper cells from activating the B cells, suggesting that the presence of self-reactive T helper cells with too few regulatory T cells may be
'"/>

Contact: Franklin Hoke
hoke@wistar.upenn.edu
215-898-3716
The Wistar Institute
16-Apr-2002


Page: 1 2 3

Related biology news :

1. Keeping your peas and carrots safe to eat
2. Keeping populations of cerulean warbler healthy
3. Keeping a tight rein on cell division
4. Keeping the cold out
5. A pathway to blocking autoimmunity
6. A new hypothesis about autoimmunity. Is it possible to be too clean?
7. Sick Kids researchers pinpoint link between diabetes and nervous system autoimmunity
8. Bacterial proteins cause autoimmunity in the antiphospholipid syndrome
9. Mechanism for generating autoimmunity-suppressing cells identified
10. Atomic structure identified for gene-regulating molecule: Broad implications for cancers, autoimmunity, developmental disorders
11. Infections may trigger autoimmunity via rare, but normal process

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Keeping autoimmunity check may depend balance the immune system

(Date:8/26/2015)... The report "Multi-Factor Authentication (MFA) Market ... (Travel & Immigration, Government, Banking, Defense, Commercial Security, Consumer ... published by MarketsandMarkets, Multi-Factor Authentication Market is expected to ... CAGR of 17.7% between 2015 and 2020. ... spread through 169 P ages and ...
(Date:8/24/2015)... CAPE TOWN, South Africa , August 24, 2015 /PRNewswire/ ... awarded Germany ,s largest biometrics manufacturer DERMALOG ... with the "2015 African Biometrics Company of the ... installation in Nigeria .   ... ) and http://www.presseportal.de/nr/8896 - On Thursday ...
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global ... and manufacture of highly valued cardiac markers used in early detection of heart ... protein chemistry has led to the development and commercialization of important cardiac biomarkers ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... and BEIJING , August 26, 2015 ... Scene with Impressive Acheivements  DiaCardio wins 1 st ... The competition, led in Israel ... featured 21 startups from countries including the US, China ... and Latin America .  Impressive ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
Cached News: